重组人脑利钠肽治疗急性非ST段抬高型心肌梗死合并心力衰竭的疗效观察

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (12): 1406-1409.

重组人脑利钠肽治疗急性非ST段抬高型心肌梗死合并心力衰竭的疗效观察

乔华, 何胜虎, 纪军, 陈述, 刘晓东, 徐日新, 谢勇

扬州大学临床医学院江苏省苏北人民医院心内科,扬州 225001,江苏

收稿日期:2010-11-07 修回日期:2010-11-23 出版日期:2010-12-26 发布日期:2020-09-16
通讯作者: 何胜虎,男,教授,硕士生导师,研究方向:冠心病的临床与基础研究。Tel: 13952796929 E-mail: sbhsh@medmail.com.cn
作者简介:乔华,女,硕士研究生,住院医师,研究方向:冠心病的临床与基础研究。Tel: 15195557141 E-mail: 110460129@qq.com

Effects of recombinant human brain natriuretic peptide in Non-ST-segment elevation acute myocardial infarction patients with heart failure

QIAO Hua, HE Sheng-hu, JI Jun, CHEN Shu, LIU Xiao-dong, XU Ri-xing, XIE Yong

Department of Cardiovascular Medicine,Medical College of Yangzhou University, Northen Jiangsu People's Hospital, Yangzhou 225001, Jiangsu , China

Received:2010-11-07 Revised:2010-11-23 Online:2010-12-26 Published:2020-09-16

摘要/Abstract

摘要： 目的: 评价重组人脑利钠肽(rhBNP)治疗急性非ST段抬高型心肌梗死(NSTEMI)合并心力衰竭的疗效及其不良反应。方法: 治疗组26 例,在常规药物治疗的基础上给予rhBNP治疗;对照组27例,给予常规药物治疗。观察两组用药前后生命体征、呼吸困难程度、脑钠肽(BNP)及相关血流动力学指标的变化。结果: 两组比较,在临床表现(包括症状、体征)、心功能分级、左室射血分数、尿量(每小时平均尿量)等方面差异有统计学意义( P＜0.05)。结论: rhBNP治疗NSTEMI合并心力衰竭的疗效显著,且安全可行。

关键词: 重组人脑利钠肽, 急性非ST段抬高型心肌梗死, 心力衰竭

Abstract: AIM: To evaluate the effect and adverse reactions of recombinant human brain natriuretic peptide(rhBNP) in Non-ST-segment elevation acute myocardial infarction patients with heart failure.METHODS: Treatment group:26 cases of conventional drug therapy based on rhBNP to the treatment; Control group: 27 patients received routine treatment. Vital signs, respiratory difficulty, BNP and related changes in hemodynamics were observed before and after treatment.RESULTS: The two groups in clinical performance(including symptoms and signs),functional class,left ventricular ejection fraction,urine volume(average urine volume per hour)and so,the difference was significant (P＜0.05).CONCLUSION: rhBNP for Non-ST-segment elevation acute myocardial infarction (NSTEMI) with heart failure have a significant effect, but a low incidence of adverse reactions.

Key words: Recombinant human brain natriuretic peptide, Non-ST-segment elevation acute myocardial infarction, Heart failure

中图分类号:

R541.4

乔华, 何胜虎, 纪军, 陈述, 刘晓东, 徐日新, 谢勇. 重组人脑利钠肽治疗急性非ST段抬高型心肌梗死合并心力衰竭的疗效观察[J]. 中国临床药理学与治疗学, 2010, 15(12): 1406-1409.

QIAO Hua, HE Sheng-hu, JI Jun, CHEN Shu, LIU Xiao-dong, XU Ri-xing, XIE Yong. Effects of recombinant human brain natriuretic peptide in Non-ST-segment elevation acute myocardial infarction patients with heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1406-1409.

参考文献

[1] 陈纪林,高润霖,张峻,等.急性非Q波心肌梗死冠状动脉病变特点分析[J].中华心血管病杂志,2001,29(12):726-727.
[2] Kawakami R,Saito Y,Kishimoto I , et al . Over expression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction[J].Circulation ,2004 ,110(21) :3306-3312.
[3] Karl S, John C,Wlson S, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary[J].Eur Heart J, 2005, 26 (6) : 1115-1140.
[4] 马虹.重组人脑利钠肽在心力衰竭治疗中的作用[J].新医学,2007, 38 (10) : 685-687.
[5] Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide,a natriuretic pep tide, in the treatment of decompensated congestive: heart failure .Nesiritide Study Group[J]. N Engl J Med, 2000, 343(4):246-253.
[6] Emerman CL.Safety and efficacy of nesiritide for the treatment of decompensated heart failure[J]. Rev Cardiovasc Med, 2002, 3 (Suppl 4):S28-34.
[7] Peacock WF, Emerman CE, Doleh M, et al. The incidence of non-ST segment elevationMI in emergency department patients p resenting with decompensated heart failure[J]. Congest Heart Fail, 2003, 9(6): 303-308.
[8] Peacock WF 4th, Emerman CL, Young J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy[J].J Card Fail, 2004, 10(2): 120-125.
[9] Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure[J].Am J Emerg Med, 2005, 23: 327-331.
[10] 吴铿,回皓声,莫振兆,等.氯沙坦联合美托洛尔治疗充血性心力衰竭的疗效观察[J]. 中国临床药理学与治疗学,1999,4(3):250-251.
[11] Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries[J]. Am J Physiol, 1999, 276 (3) : 149-157.
[12] Michaels AD, Klein A, Madden JA, et al.Effects of intravenousnesiritide on human coronary vasomotor regulation and myocardial oxygen uptake[J].Circulation, 2003, 107(21): 269-270.
[13] BurgerAJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B2 type natriuretic pep tide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study[J].Am Heart J, 2002,144(6):102-108.
[14] Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic pep tide in patients with hemodynamically decompensated heart failure[J]. J Card Fail, 1998, 4(1):37-44.
[15] Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts[J].Hypertension, 1995, 25(2): 227-234.